Skip to main content

Advertisement

SpringerLink
Log in

Dual X-ray absorptiometry detects disease- and treatment-related alterations of bone density in prostate cancer patients

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Metastatic bone disease is an important clinical problem which has proven difficult to study because of a lack of noninvasive investigative modalities. Here we show that dual-energy X-ray absorptiometry (DXA) scanning provides clinically useful information about the status of metastatic bone lesions in cancer patients undergoing palliative treatment. In the study group of 21 patients, a significant increase in metastatic bone mineral density (BMD) was confirmed in prostate (n=14) relative to breast (n=7) cancer patients. With respect to the prostate cancer cohort, further increases in lesional BMD were evident in all evaluable patients in whom biochemical progression occurred; conversely, lesional BMD declined in patients who had a partial response to therapy. BMD of uninvolved bone decreased with all types of androgen-deprivation therapy regardless of whether patients responded or relapsed. We conclude that BMD changes in both lesional and uninvolved bone are readily detectable in metastatic prostate cancer, and propose that DXA scanning represents a promising new approach to monitoring the natural history and therapeutic course of this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Belliveau RE, Spencer RP. Incidence and sites of bone lesions detected by 99mTc-polyphosphate scans in patients with tumors. Cancer 1975; 36: 359–63.

    Article  PubMed  CAS  Google Scholar 

  2. Cook G, Watson F. Events in the natural history of prostate cancer: using salvage curves, mean age distributions and contingency coefficients. J Urol 1968; 96: 87–96.

    Google Scholar 

  3. Hayward JL, Carbone PP, Heuson JC et al. Assessment of response to therapy in advanced breast cancer. Cancer 1977; 3: 1389–94.

    Google Scholar 

  4. Coleman RE. Evaluation of bone disease in breast cancer. Breast 1994; 3: 73–8.

    Article  Google Scholar 

  5. Nguyen-Pamart M, Bonneterre J, Hecquet B. Urinary excretion of deoxypyridinoline in patients with breast cancer. Anticancer Res 1995; 15(4): 1601–3.

    PubMed  CAS  Google Scholar 

  6. Delmas PD, Fontana A. Bone loss induced by cancer treatment and its management. Eur J Cancer 1998; 34: 260–2.

    Article  PubMed  CAS  Google Scholar 

  7. Hauschka PV, Manrakos AE, Iafrati MD et al. Growth factors in bone matrix. Isolation of multiple types of affinity chromatography on heparin sepharose. J Biol Chem 1986; 261: 12665–74.

    PubMed  CAS  Google Scholar 

  8. Diel IJ, Solomayer E-F, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339(6): 357–63.

    Article  PubMed  CAS  Google Scholar 

  9. McGrath SA, Diamond T. Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. J Urol 1995; 154: 535–6.

    Article  PubMed  CAS  Google Scholar 

  10. Townsend MF, Sanders WH, Northway RO et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997; 79: 545–50.

    Article  PubMed  CAS  Google Scholar 

  11. Bruning PF, Pit MJ, de Jong-Bakker M et al. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 1990; 61: 308–310.

    PubMed  CAS  Google Scholar 

  12. Powles TJ, Hickish T, Kanis JA et al. Effect of tamoxifen on bone mineral density measured by dual energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78–84.

    PubMed  CAS  Google Scholar 

  13. Love RR, Mazess RB, Barden HS, al e. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852–6.

    Article  PubMed  CAS  Google Scholar 

  14. Rodan GA. Introduction to bone biology. Bone 1992; 13 (Suppl 1): S3–S6.

    Article  PubMed  CAS  Google Scholar 

  15. Wahner HW, Fogelman I. The Evaluation of Osteoporosis. Dual X-Ray Absorptiometry in Clinical Practice. London: Martin Dunitz 1994.

    Google Scholar 

  16. Banks LM. Dual energy X-ray absorptiometry (DXA). In Grainger RG, Allison DJ (eds) Diagnostic Radiology-a Textbook for Radiologists, 3rd ed. London: Churchill Livingstone 1997; 125–36.

    Google Scholar 

  17. Kroger H, Laituieu K. Bone mineral density measured by dual energy X-ray absorptiometry in normal men. Eur J Clin Nutr 1992; 22: 454–60.

    CAS  Google Scholar 

  18. Krall EA, Dawson-Hughes B, Hirst K et al. Bone mineral density and biochemical markers of bone turnover in healthy elderly men and women. J Gerontol 1997; 52A: M61–M67.

    CAS  Google Scholar 

  19. Burgher H, van Daele PLA, Algra D et al. The association between age and bone mineral density in men and women aged 55 years and over. The Rotterdam study. J Bone Miner Res 1994; 25: 1–13.

    Article  Google Scholar 

  20. Hayward JL, Rubens RD, Carbone PP. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977; 35: 292–8.

    PubMed  CAS  Google Scholar 

  21. Shapiro CL, Keating J, Angell JE et al. Monitoring therapeutic response in skeletal metastases using dual-energy X-ray absorptiometry: A prospective feasability study in breast cancer patients. Cancer Invest 1999; 17: 566–74.

    Article  PubMed  CAS  Google Scholar 

  22. Tyrell CJ, Blake GM, Iversen P et al. 'Casodex' may preserve bone mineral density of patients with advanced prostate cancer. BJU Int BJU Intl 2000; 86 (Suppl 3): 220–1.

    Google Scholar 

  23. Group MRCPCWPI. Immediate versus deferred treatment for advanced prostate cancer: Initial results of the Medical Research Council trial. Br J Urol 1998; 79(2): 235–46.

    Google Scholar 

  24. Scher HI, Kelly WMK, Zhang Z-F et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgenindependent prostate cancer. J Natl Cancer Inst 1999; 91: 244–51.

    Article  PubMed  CAS  Google Scholar 

  25. Schwartz LH, LaTrenta LR, Bonaccio E, Kelly WK, Scher HI, Panicek DM. Small cell and anaplastic prostate cancer: Correlation between CT findings and prostate-specific antigen level. Radiology 1998; 208: 735–8.

    PubMed  CAS  Google Scholar 

  26. Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun m, Yeung H, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999; 17: 948–57.

    PubMed  CAS  Google Scholar 

  27. Pollen JJ, Witzkun KF, Ashburn WL. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. Am J Radiother 1984; 142: 773–6.

    CAS  Google Scholar 

  28. Rossleigh MA, Lovegrove FTA, Reynolds PM, Byrne MJ, Whitney BP. The assessment of response to therapy of bone metastases in breast cancer. Aust NZ J Med 1984; 14: 19–22.

    CAS  Google Scholar 

  29. Coleman RE, Rubens RD, Fogelman I. The bone scan flare following systemic treatment for bone metastases. J Nucl Med 1988; 29: 1354–9.

    PubMed  CAS  Google Scholar 

  30. Yuh WT, Zacher CK, Barloon TJ, Sato Y, Sickels WJ, Hawes DR. Vertebral compression fractures: A distinction between benign and malignant causes with MR imaging. Radiology 1989; 172: 215–8.

    PubMed  CAS  Google Scholar 

  31. Jones AL, Williams MP, Powles TJ, et al. Magnetic resonance imaging in the detection of skeletal metastases in patients with breast cancer. Br J Cancer 1990; 62: 296–8.

    PubMed  CAS  Google Scholar 

  32. Coleman RE. Monitoring of bone metastases. Eur J Cancer 1998; 34(2): 252–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Metabolic Medicine, Urology, Imperial College School of Medicine, Singapore

    Gillian L. Smith

  2. Urology, Medical Oncology, Imperial College School of Medicine, Singapore

    Alan P. Doherty

  3. Imaging, Imperial College School of Medicine, Singapore

    Linda M. Banks

  4. Department of Radiology, Imperial College School of Medicine, Singapore

    Jane Dutton

  5. Radiotherapy, Imperial College School of Medicine, Singapore

    Iain W. Hanham

  6. Urology, Imperial College School of Medicine, Singapore

    Timothy J. Christmas

  7. Metabolic Medicine, Imperial School of Medicine, National Cancer Centre, Singapore

    Richard J. Epstein

Authors
  1. Gillian L. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan P. Doherty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Linda M. Banks
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jane Dutton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Iain W. Hanham
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Timothy J. Christmas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Richard J. Epstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smith, G.L., Doherty, A.P., Banks, L.M. et al. Dual X-ray absorptiometry detects disease- and treatment-related alterations of bone density in prostate cancer patients. Clin Exp Metastasis 18, 385–390 (2000). https://doi.org/10.1023/A:1010991213842

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1010991213842

Search

Navigation